Christine Ring - 20 Jan 2026 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Chief Legal Officer
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring
Issuer symbol
NRIX
Transactions as of
20 Jan 2026
Net transactions value
-$62,280
Form type
4
Filing time
20 Jan 2026, 19:57:57 UTC
Previous filing
18 Dec 2025
Next filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ring Christine Chief Legal Officer C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE /s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring 21 Jan 2026 0001817199

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRIX Common Stock Options Exercise $6,994 +3,760 +7.4% $1.86 54,657 20 Jan 2026 Direct F1
transaction NRIX Common Stock Sale $69,273 -3,760 -6.9% $18.42 50,897 20 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Options Exercise $0 -3,760 -30% $0.000000 8,643 20 Jan 2026 Common Stock 3,760 $1.86 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2 Represents the weighted average sale price. The lowest price at which shares were sold was $18.18 and the highest price at which shares were sold was $18.69. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3 The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.